Rethinking brain health
We are on a mission to change the way the world thinks about brain health.
Oxford Brain Diagnostics is committed to analysing the cellular structure of the brain in a way no one else can, to support drug development and aid clinicians around the world in their fight to defeat Alzheimer’s and other neurodegenerative conditions.
Our novel technology assesses brain health based on changes in the cellular structure.
Our pioneering approach, and novel measures unlock unique insights that enable us to predict, detect, quantify, track and differentiate neurodegenerative conditions.
This gives us the potential to revolutionise how people think about brain health.
Supporting more efficient drug development and personalised patient care.
Previously inaccessible insights unlocked by our proprietary technology will support more targeted, efficient drug development.
Our products
Pharma/Biotech
- Measures you can trust
- Get more from your MRI
- Run targeted, more efficient clinical trials
- Efficient use of technology across multiple conditions
Clinical
- Supporting patient care
- Helping clinicans in their diagnosis
- Differential patterns of brain changes
- Accurately tracking changes
- Proactive brain health
Latest news
Oxford Brain Diagnostics Joins International Consortium in $650K Fox Foundation Grant
Oxford Brain Diagnostics is collaborating with top North American institutions on a 24-month project to detect early-stage Parkinson’s using advanced MRI and their FDA cleared technology - Cortical Disarray Measurement. Funded by The Michael J. Fox Foundation, the initiative aims to develop objective biomarkers to improve diagnosis, treatment, and clinical trials in PD.
BGF backed Oxford Brain Diagnostics to roll out technology for early diagnosis of dementia
Oxford Brain Diagnostics has gained FDA 510(k) and UKCA clearance for its CDM Insights software, which uses standard MRI scans to detect neurodegeneration and support early dementia diagnosis. Backed by a major 2023 investment from BGF, the company is expanding into US and UK healthcare markets. Already partnering with pharmaceutical companies for clinical trials, OBD's platform represents a significant breakthrough in the fight against neurodegenerative diseases like AD, PD and MS.
Gail Marcus joins OBD Board as Chair Person
We proudly welcome Gail Marcus to our board as Chair Person and we also congratulate Andrew Barker on his retirement from the role and thank him for his 6 years dedicated to leading the Board. "Chairing the board of Oxford Brain Diagnostics during this exciting chapter has been a privilege. The company is well-positioned for long-term success, and I look forward to its continued development."Andrew said. Gail's expertise in healthcare and biotech brings incredible value to our mission of changing how the world thinks about brain health. With an impressive track record spanning Fortune 100 companies like CIGNA and United Healthcare, as well as early-stage ventures in the US and UK, Gail brings a wealth of experience in healthcare, biotech, and diagnostics. She is serving on public and private boards, and holds deep expertise in governance, finance, and risk management. With her strategic insight and deep industry knowledge, we are set to accelerate our mission and drive meaningful change.
Oxford Brain Diagnostics has been granted FDA Clearance for its novel MRI Software – CDM Insights
Oxford Brain Diagnostics announces U.S. FDA Clearance of CDM Insights. This sets a new standard in measuring and monitoring brain microstructure and macrostructure. CDM Insights (powered by Cortical Disarray Measurement) is a non-invasive solution that automatically conducts deep analysis of standard clinical MRI brain scans to provide detailed insights into microstructural composition. This novel technology aims to empower healthcare practitioners seeking to diagnose neurodegenerative conditions like Alzheimer’s disease. With FDA 510(k) clearance, CDM Insights has proven to be a safe and effective tool for healthcare providers.
